Invivyd reported Q4 2024 revenue of $13.8 million, highlighting significant growth and ongoing development of COVID-19 treatments PEMGARDA and VYD2311. Invivyd, Inc. reported a net product revenue ...

We are delighted by Ajay’s return to the Board of Invivyd as the company prepares to take the next step forward in scaling the medical benefit from its core technologies. Invivyd has rapidly ...

March 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced financial ...

Invivyd has a fifty-two week low of $0.35 and a fifty-two week high of $4.74. Invivyd ( NASDAQ:IVVD – Get Free Report ) last issued its quarterly earnings data on Thursday, March 20th.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

March 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced financial results ...